Please assess the completion status of the following clinical trial:

Trial Title: Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Pre-Entry Criteria~Women were eligible for the study if they:~* have evidence of HIV infection (documented by two HIV antibody tests on two different dates);~* were to be provided ZDV Prophylaxis (starting at 28 weeks or as soon as possible thereafter);~* intended to carry the pregnancy to term;~* intended to deliver at and bring their infant to a study site for at least 12 months after delivery; and~* could provide informed consent.~Inclusion criteria~Women are eligible for the study if they:~* met all pre-entry criteria;~* agreed not to breastfeed;~* consented to participate and to be followed for the duration of the study;~* presented the following laboratory values within 14 days prior to randomization:~* hemoglobin \> 8.0 mg/dl~* absolute neutrophil count \> 1000 cells/mm3~* platelets \> 100,000 cells/mm3~* serum creatinine \< 1.5 mg/dl (women with a serum creatinine \> 1.5 mg/dl must have a measured eight-hour urine creatinine clearance \> 70 ml/min)~* SGPT less than 10 times the upper limit of normal NOTE: Women with a Grade 2 or Grade 3 SGPT value (between 2.6 and 10 times the upper limit of normal) were allowed on study; they were monitored monthly until delivery. If at any point their SGPT value rose to a Grade 4 (more than 10 times the upper limit of normal), they should not be dosed with the Study Drug.~Exclusion Criteria:~* evidence of pre-existing fetal anomalies incompatible with life;~* known hypersensitivity to any benzodiazepine or to NVP;~* receipt of antiretroviral agent other than ZDV;~* receipt of non-allowed concomitant treatment;~* uncontrolled hypertension;~* concurrent participation in another clinical trial;~* women with a CD4 count \<200/µL or history of oral candidiasis if they were not receiving PCP prophylaxis.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
- 2 (Type: EXPERIMENTAL): One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
- 3 (Type: PLACEBO_COMPARATOR): One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).